MindImmune Therapeutics, Inc.
PrivateLast Round
Convertible Debt
Mar 5, 2026
Est. Valuation
$22.4M
Total Funding Raised
$52.97M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
MindImmune Therapeutics, Inc. is a biotechnology company that develops antibody-based drugs and therapeutics designed to treat diseases of the central nervous system by targeting neuroinflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MindImmune Therapeutics, Inc. Comparables
Compare MindImmune Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Muna Therapeutics | 80% | |
| Allyx Therapeutics, Inc. | 78% | |
| INmune Bio Inc | 76% | |
MindImmune Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 5, 2026 | ||||
| Series A | Nov 24, 2025 | ||||
| Grant | Jun 1, 2025 | ||||
| Series A | Jun 14, 2022 | ||||
| Grant | Jan 1, 2022 | ||||
Seed | Aug 21, 2017 |
Key People
Founding team and executive leadership
MindImmune Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A |
| Rhode Island Life Science Hub | Grant |
| The Foundation For A Better World | Series A |
| Pfizer Ventures | Series A |
| RightHill Ventures | Series A |
| Pfizer | Series A |
| Slater Technology Fund | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Raised $5M in a VC Round.
- Nov 26, 2025
Isaac Stoner appointed as the new Chief Executive Officer.
MindImmune Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MindImmune Therapeutics, Inc.'s valuation, stock price, and market status.